Claims for Patent: 5,861,502

Summary for Patent: 5,861,502

Title:	Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen
Abstract:	The present invention is directed to oligonucleotides that inhibit mutant COL1A1 and/or wild type COL1A1 gene expression. The present invention is further directed to methods of inhibiting mutant and/or wild type collagen gene expression using the disclosed inhibitory oligonucleotides. The oligonucleotides and methods of the present invention are useful for the treatment of mammals having diseases related to inappropriate mutant or wild type COL1A1 gene expression.
Inventor(s):	Prockop; Darwin (Philadelphia, PA), Colige; Alain (Sart Tilman Par Liege, BE), Baserga; Renato (Ardmore, PA), Nugent; Paul (Philadelphia, PA)
Assignee:	Thomas Jefferson University (Philadelphia, PA)
Application Number:	08/432,158
Patent Claims:	1. An oligonucleotide consisting of 10 to 50 nucleotides having a nucleotide sequence that stably hybridizes in a cell in culture to the exon 1/intron 1 boundary of a mutant or normal wild type COL1A1 gene encoding pro.alpha.1(I) chain of type I procollagen, wherein said oligonucleotide inhibits expression of said mutant or normal wild type COL1A1 gene. 2. The oligonucleotide of claim 1 of SEQ ID NO: 18. 3. The oligonucleotide of claim 1 in a pharmaceutically acceptable carrier or diluent. 4. An oligonucleotide consisting of a sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO: 10, SEQ ID NO:11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:23. 5. A method of inhibiting mutant collagen gene expression in a cell in culture which comprises contacting a cell containing a mutant COL1A1 gene with an inhibitory amount of an oligonucleotide consisting of 10 to 50 nucleotides having a nucleotide sequence that stably hybridizes to the exon 1/intron 1 boundary of said mutant COL1A1 gene. 6. The method of claim 5 wherein said oligonucleotide consists of SEQ ID NO: 18. 7. A method of inhibiting normal collagen gene expression in cell culture which comprises contacting a cell containing a normal COL1A1 gene with an inhibitory amount of an oligonucleotide consisting of 10 to 50 nucleotides having a nucleotide sequence that stably hybridizes to the exon 1/intron 1 boundary of said normal COL1A1 gene.

Details for Patent 5,861,502

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2012-11-09
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2012-11-09
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2012-11-09